Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution

per Nuno Cerveira, Bruno Loureiro, Susana Bizarro, Cecília Correia, Lurdes Torres, Susana Lisboa, Joana Vieira, Rui Santos, Dulcineia Pereira, Cláudia Moreira, Sérgio Chacim, Nélson Domingues, Ana Espírito-Santo, Isabel Oliveira, Ilídia Moreira, Luísa Viterbo, Ângelo Martins, Manuel R. Teixeira, José M. Mariz
Publicat 2018-12-01